CJC-1295 side effects haven't been counted well in people
Small studies watched hormones, not harm that is rare or appears years later. Swelling, blood sugar, cancer, and immune questions remain.
Small studies can't settle safety over years
To make a hormone message last, the drug company ConjuChem developed CJC-1295. Early studies measured that effect, not uncommon harm months or years later.
Side effects aren't well counted in healthy adults. No large or long study tells you how often harm occurred [7].
The testing plan for long-form CJC-1295 DAC stopped. The public listing doesn't give a plain reason, and the drug still isn't approved for people [7].
The stopped CJC-1295 trial isn't proof that the drug caused harm. It does mean the work never supplied the safety answers a larger study might have given.
Researchers followed growth hormone and IGF-1 in small groups. That IGF-1 work didn't keep checking those people for years to find harm that appears late [1][3][7].
When growth hormone rises, your body may hold more water. Insulin may also have more trouble moving sugar out of your blood [14].
Higher IGF-1 is tied to a slightly greater chance of some cancers. That link doesn't prove CJC-1295 causes cancer [14].
FDA papers in 2024 raised the chance of an immune reaction. In plain words, your body's defenses might attack the drug [13].
The proof can't yet show that CJC-1295 is safe
No large safety study has followed people long enough to answer that question for you. The DAC work stopped, while questions about IGF-1 and other hormone effects remain [13][14].
CJC-1295 hasn't won approval anywhere [7]. That doesn't prove harm, but it leaves safety unsettled.
The peptide still lacks a long safety record
Only small early groups received CJC-1295. No study followed long use, and the DAC testing plan ended [13][7].
FDA papers also raised a possible immune reaction. Published studies of CJC-1295 and IGF-1 don't support calling the drug safe.
Possible harms are concerns, not known rates
ConjuChem's plan for the long DAC form ended before approval. A Phase 2 trial enrolled adults living with HIV who carried extra fat deep in the abdomen, then stopped without settling safety [7].
Reports often connect a patient's death with that period, but the public record gives you neither a cause nor a finding that the drug played any part in the death. CJC-1295 therefore remains tied to an unanswered report, not a proved cause.
The cause remains unknown. It would be wrong to turn an unanswered question into proof against the drug.
Growth hormone and IGF-1 can bring swelling and make insulin work less well [14]. Insulin helps cells move sugar out of your blood.
A higher IGF-1 reading goes with a modestly greater chance of some cancers. That IGF-1 link is a reason for care, not proof that CJC-1295 causes cancer.
In 2024, FDA advisers also warned that your body's defenses might attack the drug [13]. They couldn't say how often that might happen.
No CJC-1295 safety study gives a sound count for any of these harms. The early groups were too small for that.
The FDA wouldn't let pharmacies use CJC-1295 as the main ingredient in patient drugs they mix [13]. The lack of good safety proof helped shape that choice.
Only small early groups got the drug, and the longer plan ended [7][13]. You are still left without the answers that long follow-up could give.
No study tells you how often CJC-1295 causes these problems
No study comparing groups counted harm in healthy adults [7]. Growth hormone can cause water gain and swelling.
It may also make insulin work less well. Higher IGF-1 has cancer links, and the FDA raised a different concern about the immune system [13][14].
These are possible harms, including the IGF-1 concern, not known rates. No CJC-1295 study has shown how often any one occurs.
CJC-1295 studies didn't measure testosterone
CJC-1295 works through growth hormone, not the controls for testosterone [2]. Published studies checked IGF-1 and weren't designed to test testosterone [3].
Because testosterone wasn't measured, the studies could not tell whether testosterone went up or down. Any claim about a change goes beyond their work.
Published work doesn't show that CJC-1295 lowers testosterone
No published CJC-1295 study reports lower testosterone [2][3]. The researchers measured growth hormones instead.
The claim that CJC-1295 lowers testosterone remains unproved. These studies made no finding about that question.
